Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Not Applicable

Not yet recruiting

• Conditions: Cervical Cancer; Immunochemotherapy
• Interventions: Drug: Camrelizumab combined with chemotherapy

• Registration Number: NCT07167160
• Lead Sponsor: Women's Hospital School Of Medicine Zhejiang University

Brief Summary

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study Start: 2025-09-01
• Study First Submitted: 2025-09-01
• Study First Submitted QC: 2025-09-09
• Last Update Submitted: 2025-09-09
• Study First Posted: 2025-09-11
• Last Update Posted: 2025-09-11
• Primary Completion: 2026-12-31
• Study Completion: 2029-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 59

Inclusion Criteria

1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
2. Positive PD-L1 expression;
3. ECOG score ≤1

Exclusion Criteria

1. Positive parametrium or surgical margin;
2. Incomplete radical surgery;
3. Residual target lesions;
4. Active autoimmune disease or autoimmune disease requiring systemic treatment;
5. Previous treatment with immune checkpoint inhibitors.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
chemotherapy group	Camrelizumab combined with chemotherapy	-

Primary Outcome Measures

Name	Time	Method
3-year disease-free survival rate	from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months

Trial Locations

Locations (1)

Women's Hospital, School of Medicine, Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China